Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Bioactive Lipids of Cardiorespiratory Fitness Insights From Exercise Models in Humans, Mice, and Burmese Pythons

Guseh JS, Roshandelpoor A, Alotaibi M, Zarbafian S, Lau ES, Kuznetsov A, Rosenzweig A, Saeidi N, Choudhary A, Jain M, Cheng S, Lewis GD, Ho[...]

Improved plaque composition from intensive medical treatment in women with angina and non-obstructive coronary disease

Lenell J, Flores Tomasino G, Han D, Wolny R, Park C, Grodecki K, Kwiecinski J, Xing E, Manral N, Asebiomo F, Goyal D, Calsavara VF,[...]

Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE: Improved Functional 90-Day Outcomes in STORM-PE RCT

Rosovsky RP, Konstantinides SV, Weinberg I, Dohad SY, Rosol Z, Stępniewski J, Moriarty JM, Parikh SA, Holden A, Channick RN, McDonald B, Nagarsheth KH, Matusov[...]